6L8 Stock Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pulse Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.20 |
| 52 Week High | US$11.40 |
| 52 Week Low | US$3.54 |
| Beta | 1.7 |
| 1 Month Change | -24.39% |
| 3 Month Change | -21.52% |
| 1 Year Change | 18.10% |
| 3 Year Change | -63.95% |
| 5 Year Change | -58.57% |
| Change since IPO | -70.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6L8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -14.5% | 1.7% | 1.7% |
| 1Y | 18.1% | -7.7% | 2.3% |
Return vs Industry: 6L8 exceeded the German Medical Equipment industry which returned -9.5% over the past year.
Return vs Market: 6L8 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| 6L8 volatility | |
|---|---|
| 6L8 Average Weekly Movement | 11.6% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6L8's share price has been volatile over the past 3 months.
Volatility Over Time: 6L8's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 61 | Kevin Danahy | www.pulsebiosciences.com |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. Fundamentals Summary
| 6L8 fundamental statistics | |
|---|---|
| Market cap | €353.99m |
| Earnings (TTM) | -€39.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.0x
P/E RatioIs 6L8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6L8 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.21m |
| Earnings | -US$42.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6L8 perform over the long term?
See historical performance and comparison